Navigation Links
Cancer Cell Article Demonstrates First Definitive Evidence for Targeting of Pol I as New Approach to Cancer Therapy
Date:7/10/2012

ac later this year."

The Cancer Cell publication highlighted a number of potential competitive advantages of CX-5461.  An unanticipated finding was that malignant cells are considerably more dependent upon maintenance of high levels of Pol I activity than previously believed, and even modest inhibition of Pol I triggers cancer cell death. These results suggest that selective activation of a surveillance pathway to activate p53, using Pol I inhibitors such as CX-5641, is likely to be therapeutically useful in the treatment of a wide range of tumors. In addition, as a cancer-specific inducer of p53, CX-5461 was shown to be 300 times more potent than currently studied non-genotoxic p53 activators with alternate mechanisms.

About Pol I and CX-5461 CX-5461 is a first-in-class, selective small molecule inhibitor of RNA polymerase I (Pol I) that triggers a stress surveillance pathway to activate p53 in cancer cells. The tumor suppressor protein p53, known as "the guardian of the genome," orchestrates cellular responses to diverse stress factors. Activation of this protein can lead to cell cycle arrest or cell death and it is pivotal in determining whether cancer cells proliferate or die. CX-5461 inhibits upregulated Pol I transcription in cancer cells, causing the release of ribosomal proteins (RP) from the nucleolus. These RP then bind to Mdm2, liberating p53 from the Mdm2-p53 complex to induce apoptosis in cancer cells. Non-genotoxic activation of p53 has long been an attractive approach to treating cancers, but it has not yet been successfully exploited in the clinic. CX-5461 has therapeutic potential in both solid tumor and hematological malignancies, yet hematologic cancers, the vast majority of which have wild-type p53 status, are exquisitely sensitive to CX-5461 and represent the clearest path to clinical proof of concept.

About Cylene Pharmaceuticals Cylene Pharmaceuticals is a clinical stage private company developing small molecu
'/>"/>

SOURCE Cylene Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. QIAGEN Achieves Personalized Healthcare Milestone with U.S. Approval of Companion Diagnostic for Colorectal Cancer
2. Oncos Therapeutics Announces Clinical Advisory Board for its Oncolytic Virus and Cancer Immunotherapy Development Programs
3. Ovarian Cancer Therapeutics - Global Drug Forecasts and Treatment Analysis 2020
4. Global Kidney Cancer Drugs Industry
5. Trovagene to Study Trans-Renal KRAS Mutation Detection in Pancreatic Cancer
6. Prostate Cancer Center of New Jersey the Latest Center to Achieve High Honor of ACR-ASTRO Accreditation
7. Lifeline Biotechnologies, Inc. Receives Patent Award, a Device for Breast Tissue Temperature Analysis for Determining Cancer Conditions
8. U.S. FDA Grants Priority Review to the New Drug Application for Bayers Regorafenib to Treat Patients with Metastatic Colorectal Cancer
9. Aethlon Medical (AEMD) Note: Cancer Treatment Publication Authored by Aethlon Medical Researchers Now Available
10. Elektas Gamma Knife and Radiation Therapy Systems for Cancer Treatment Take Top Three Places in 2012s Best in KLAS for Radiation Therapy
11. Healthscope to commercially launch Circadians Cancers of Unknown Primary Diagnostic Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... -- Burzynski Research Institute, Inc. (BRI) announced today that ... the company permission to conduct an open-label study of ... of age with a diffuse intrinsic brainstem glioma (DIPG). ... treatment groups based on their age and whether or ... primary study endpoint is a decrease in the size ...
(Date:10/22/2014)... , Oct. 22, 2014  Medical ... laboratory which specializes in high complexity, state-of-the-art, ... is now offering new Cystic Fibrosis Testing ... generation DNA sequencing platforms. Cystic ... inherited multisystem disorder that affects the respiratory, ...
(Date:10/22/2014)... MADISON, N.J. , Oct. 22, 2014  Quest ... provider of diagnostic information services, today announced that its ... Ph.D., to serve as a director, effective December 1, 2014. ... Dr. Leiden is the Chairman, President and CEO ... 20 years of scientific and commercial experience in the ...
Breaking Medicine Technology:Burzynski Research Institute, Inc. Announces FDA Permission to Launch a New Clinical Trial in Diffuse Intrinsic Brainstem Glioma 2Medical Diagnostic Laboratories, L.L.C. Institute for Biomarker Research Announces New Prenatal Cystic Fibrosis Tests 2Quest Diagnostics Adds Jeffrey M. Leiden, M.D., Ph.D., to Board of Directors 2Quest Diagnostics Adds Jeffrey M. Leiden, M.D., Ph.D., to Board of Directors 3
(Date:10/25/2014)... The Wehrman Collaborative, LLC (WeCo) ... disabled users by disabled users, has granted use ... Educational Resources of Burnsville, Minnesota, for their ... the Minnesota Alliance for Patient Safety of Minneapolis, ... website. Both organizations have met WeCo’s Standards ...
(Date:10/25/2014)... Everett, WA (PRWEB) October 25, 2014 ... their insulation has ‘gone bad’ need wonder no more. ... that homeowners should watch out for when it ... Bad insulation, according to the article released by Clean ... emphasize for homeowners that any insulation that has deteriorated, ...
(Date:10/25/2014)... Lyme, CT (PRWEB) October 25, 2014 ... an upcoming episode of Innovations with Ed Begley Jr, ... show times TBA. , In this episode, Innovations will ... solution helping to protect fragile, thinning skin on arms, ... Viewers will learn about these versatile products, which help ...
(Date:10/25/2014)... -- Not getting the right amount of sleep might ... suggests. Those who sleep less or more than ... be more prone to developing the chronic condition, which ... authors concluded that duration and quality of sleep are ... bowel diseases. "Both short and long durations of ...
(Date:10/25/2014)... Current osteoporosis screening guidelines and tools fail to ... osteoporosis-related fractures, a new study says. "If ... that help us accurately predict who will suffer ... these at-risk people for preventive measures," study author ... division of general internal medicine and health services ...
Breaking Medicine News(10 mins):Health News:IT-Accessibility Award Granted to Education and Health Care for Section 508/WCAG 2Health News:IT-Accessibility Award Granted to Education and Health Care for Section 508/WCAG 3Health News:5 Signs Indicating That Insulation Needs Replacing as Told By Clean Crawls in Recent Article 2Health News:Upcoming Episode of Innovations with Ed Begley, Jr. to Feature Limbkeepers® 2Health News:Sleep Duration Linked to Ulcerative Colitis Risk in Study 2Health News:Osteoporosis Screening Guidelines May Miss Younger Women at Risk 2
... Free ... Burrill & Co., BioAnalytics Group, ChanTest, GE Healthcare, Profectus Biosciences, Protagen, UNiConnect, and More ... Boston, MA ... online events for the healthcare, education and energy markets, and LabRoots , a ...
... Health Spending to Reach $1,318 per Person by 2018 ... report released today based on research by Emory ... Partnership to Fight Chronic Disease (PFCD), shows increasing obesity rates in ... care spending for states and individuals. The study, which was commissioned ...
... finds adults with records were more likely as tots to not ... are fearless at 3 years of age might just be poised ... poor fear conditioning at the tender age of 3 can ... other factors, such as education of the parents, large family size, ...
... ... Call Center , ... (PRWEB) November 17, 2009 -- VoiceNation, a leader in voicemail and ... powerful Customer Relationship software package. TASterix was chosen for its reliability, scalability and ...
... Richard ... civil damages award known in Berks County. The personal injury lawyer represented a ... Jurewicz negotiated with the Austrian manufacturer of the machine and won a settlement in ... ...
... ... manufacturer of support surface products for medical applications, introduces the ROHO Hybrid Elite cushion. ... DRY FLOATATION® with the stability of a Jay® contoured foam base engineered specifically for ... Belleville, ...
Cached Medicine News:Health News:BioConference Live Kicks-off Three Day Online Event for Life Science and Biotech Communities Today at 9:00 AM Eastern 2Health News:BioConference Live Kicks-off Three Day Online Event for Life Science and Biotech Communities Today at 9:00 AM Eastern 3Health News:Obesity Rates Will Continue to Increase, Drive Health Care Costs in New Jersey in Next Decade, According to New Study 2Health News:'Fearless' 3-Year-Olds Might Be Tomorrow's Criminals 2Health News:'Fearless' 3-Year-Olds Might Be Tomorrow's Criminals 3Health News:VoiceNation Calls on TASterix as Their CRM Solution 2Health News:Galfand Berger Personal Injury Lawyer Richard Jurewicz Obtains Record Recovery In Berks County 2Health News:The ROHO Group Introduces ROHO Hybrid Elite™ Two Trusted Brands; One Effective Cushion 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: